Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Thermo Fisher QuantStudio 3D Rare Mutation Analysis

Premium

Thermo Fisher Scientific this week announced the release of the QuantStudio 3D Rare Mutation Analysis solution.

The new offering is a panel of wet-lab validated TaqMan SNP genotyping assays and an enhanced software tool that enables researchers to detect and quantify 40 of the most common mutations in cancer genes, including EGFR, BRAF, KRAS, PIK3CA, and JAK2, at a prevalence as low as 0.1 percent.

The primary and secondary software enhancements are also designed with specific features for analysis of low-frequency alleles on the QuantStudio 3D Digital PCR system.

"Our laboratory is investigating methods to quantify the presence of mutations in cancer-related genes in circulating free DNA," Atocha Romero, a researcher in the Molecular Oncology Laboratory of Hospital Clinico San Carlos in Madrid, Spain, said in a statement. "We have tested the PIK3CA H1047R Custom TaqMan SNP Genotyping Assay on the QuantStudio 3D Digital PCR System, and we have observed that the sensitivity we can achieve with this assay is far superior than with other approaches. This assay meets all of our requirements for quantifying low-frequency mutations in circulating-free DNA."

The QuantStudio 3D system and new assays are for research use only.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.